NCT02349048View on ClinicalTrials.gov

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

May 31, 2016

Conditions
Hepatitis C Virus
Interventions
DRUG

Simeprevir 150 mg

Simeprevir 150 mg capsule orally once daily.

DRUG

Daclatasvir 60 mg

Daclatasvir 60 mg tablet orally once daily.

DRUG

Sofosbuvir 400 mg

Sofosbuvir 400 mg tablet orally once daily.

Trial Locations (8)

Unknown

Bakersfield

Jacksonville

Lutherville

Winston-Salem

Knoxville

Arlington

San Antonio

Toronto

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02349048 - Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection | Biotech Hunter | Biotech Hunter